Liquid Chromatography-Tandem Mass Spectrometry Method for Detection and Quantification of Meloxicam and 5 '-Carboxymeloxicam in Oral Fluid Samples

Author(s)

Oliveira, Gabriela Moraes ; Dionisio, Thiago Jose ; Siqueira-Sandrin, Viviane Silva ; Ferrari, Leticia Alves de Lima ; Colombini-Ishikiriama, Bella Luna ; Faria, Flavio Augusto Cardoso ; Santos, Carlos Ferreira ; Calvo, Adriana Maria

• Document type: Journal article
• Source: METABOLITES; v. 13, n. 6, p. 14-pg., 2023-06-01.

Abstract

A sensitive, selective and particularly fast method of liquid chromatography-tandem mass spectrometry (LC-MS/MS) was developed and validated for the determination of meloxicam and its main metabolite, 50-carboxymeloxicam, in oral fluid samples. Meloxicam and its major metabolite were separated using a Shim-Pack XR-ODS 75 L x 2.0 column and C18 pre-column at 40 degrees C using a mixture of methanol and 10 mM ammonium acetate (80:20, v/v) with an injection flow rate of 0.3 mL/min. The total time of the analytical run was 5 min. Sixteen volunteers had oral fluid samples collected sequentially before and after taking a meloxicam tablet (15 mg) for up to 96 h. With the concentrations obtained, the pharmacokinetic parameters were determined using the PhoenixWinNonlin software. The parameters evaluated for meloxicam and 50-carboxymeloxicam in the oral fluid samples showed linearity, accuracy, precision, medium-quality control (MQC78.12 ng/mL), high-quality control (HQC-156.25 ng/mL), lower limits of quantification (LLOQ-0.6103 ng/mL), low-quality control (LQC-2.44 ng/mL), stability and dilution. Prostaglandin E-2 (PGE(2)) was also detected and quantified in the oral fluid samples, demonstrating the possibility of a pharmacokinetic/pharmacodynamic (PK/PD) study with this methodology. All the parameters evaluated in the validation of the methodology in the oral fluid samples proved to be stable and within the possible variations in each of the described parameters. Through the data presented, the possibility of a PK/PD study was demonstrated, detecting and quantifying meloxicam, its main metabolite and PGE(2) in oral fluid samples using LC-MS/MS. (AU)

• FAPESP's process: 17/12725-0 - Model of pharmakinetics/pharmacodynamics (PK/PD) on the influence of P450 genetic polymorphism (CYP2C9) of non-steroidal anti-inflammatory drugs and main metabolics from saliva samples through LCMS/MS and its role on prescription personalization
• Grantee: Adriana Maria Calvo
• Support Opportunities: Research Grants - Young Investigators Grants
• FAPESP's process: 22/11140-7 - Pharmagenetic study and PK/PD after application of infiltrative lidocaine associated or not with epinephrine in saliva samples by LC MS/MS
• Grantee: Adriana Maria Calvo
• Support Opportunities: Regular Research Grants